1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

European Biosimilars Have ‘Room To Grow’ On Access And Understanding

Adrian Van Den Hoven, DG Of Medicines For Europe, Discusses Opportunities

 
• By Dave Wallace

In terms of broadening both access to treatment and stakeholder understanding, there remains plenty of room for growth for biosimilars in Europe, Medicines for Europe director general Adrian van den Hoven tells Generics Bulletin in an exclusive interview.

Adrian van den Hoven at Medicines for Europe's 18th Biosimilar Medicines Conference
Adrian van den Hoven shares his views on biosimilars in Europe • Source: Medicines for Europe

The European biosimilars industry was offered a boost by a recent affirmative statement from the European Medicines Agency and Heads of Medicines Agencies confirming the scientific rationale supporting the interchangeability of biosimilars and biologics, while momentum is also building in Europe to streamline regulatory processes governing biosimilars.

However, amid these positive developments there still remains room for the industry to help further broaden access to biologic treatments in Europe, as well as to enhance stakeholder understanding of biosimilars,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

More from Products